SCHEMBL10249106

SCHEMBL10249106

CCCCOc1cnccc1-c1nc2cc(C)ccc2n1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 2/20 0.46
TLR8 Q9NR97 2/20 0.42
AGPAT2 O15120 1/20 0.39
MAPT P10636 4/20 0.39
PDE2A O00408 2/20 0.38
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 2/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
ATM Q13315 1/20 0.37
PDE5A O76074 1/20 0.36
NLRP3 Q96P20 1/20 0.36
TSHR P16473 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10248845 0.94 SMN1; SMN2 (0.46) SMN1; SMN2POLBTLR8AGPAT2MAPT
SCHEMBL10248909 0.90 SMN1; SMN2 (0.48) SMN1; SMN2POLBTLR8AGPAT2MAPT
SCHEMBL10249052 0.89 MAPT (0.46) SMN1; SMN2POLBAGPAT2MAPTKDM4E
SCHEMBL175678 0.86 POLB (0.42) SMN1; SMN2POLBAGPAT2PDE2AKDM4E
SCHEMBL10249174 0.83 SMN1; SMN2 (0.45) SMN1; SMN2POLBAGPAT2MAPTKDM4E
SCHEMBL10249166 0.83 SMN1; SMN2 (0.61) SMN1; SMN2POLBAGPAT2MAPTPDE2A
SCHEMBL10248867 0.82 SMN1; SMN2 (0.44) SMN1; SMN2POLBAGPAT2MAPTPDE2A
SCHEMBL10249209 0.81 SMN1; SMN2 (0.43) SMN1; SMN2POLBAGPAT2MAPTKDM4E
SCHEMBL169479 0.81 POLB (0.42) SMN1; SMN2POLBAGPAT2PDE2A
SCHEMBL10249163 0.80 SMN1; SMN2 (0.48) SMN1; SMN2POLBAGPAT2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885TLR8 1828/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885TLR8 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.